AIFM2 and cancer: Moreover, the oncosuppressive effects of Fsp1 deletion persisted (1) in orthotopic LUAD models established in immunocompetent and immunodeficient hosts, and (2) in a large panel of LUAD cell lines irrespective of oncogenic driver, indicating that FSP1 supports in vivo LUAD progression in a cancer cell-intrinsic manner.2